Leasing health technologies- an affordable and effective reimbursement strategy for innovative technologies?
The challenge of implementing high cost innovative technologies in health care systems operating under significant budgetary pressure has seen a radical shift in the health technology reimbursement landscape. New reimbursement strategies attempt to reduce the risk of making the wrong decision; i.e. paying for a technology that is not good value for the health care system, whilst promoting the adoption of innovative technologies into clinical practice. However, the remaining risk is not shared between the manufacturer and the health care payer at the individual purchase level; it continues to be passed from the manufacturer to the payer at the time of purchase. In this paper we propose a health technology payment strategy – Technology Leasing Reimbursement Scheme (TLRS) - which allows the sharing of risk between the manufacturer and the payer; the replacing of upfront payments with a stream of payments spread over the expected duration benefit from the technology, subject to the technology delivering the claimed health benefit. Using trastuzumab (Herceptin) in Early Breast Cancer as an exemplar technology we show how a TLRS not only reduces the total budgetary impact of the innovative technology, it also truly shares risk between the manufacturer and the health care system, whilst reducing the value of further research and thus promoting the rapid adoption of innovative technologies into clinical practice.
|Date of creation:||2013|
|Date of revision:|
|Contact details of provider:|| Phone: Charles Thackrah Building, 101 Clarendon Road, LEEDS LS9 2LJ|
Fax: +44 (0) 113 343 3470
Web page: http://medhealth.leeds.ac.uk/auhe
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Christopher McCabe & Karl Claxton & Anthony J. Culyer, 2008.
"The NICE Cost-Effectiveness Threshold: What it is and What that Means,"
Springer Healthcare | Adis, vol. 26(9), pages 733-744.
- McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
- Tania Stafinski & Christopher J. McCabe & Devidas Menon, 2010. "Funding the Unfundable: Mechanisms for Managing Uncertainty in Decisions on the Introduction of New and Innovative Technologies into Healthcare Systems," PharmacoEconomics, Springer Healthcare | Adis, vol. 28(2), pages 113-142.
- Christopher McCabe & Richard Edlin & Peter Hall, 2013.
"Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?,"
Springer, vol. 31(9), pages 731-737, September.
- Christopher McCabe & Richard Edlin & Peter Hall, 2012. "Navigating time and uncertainty in health technology appraisal: would a map help?," Working Papers 1201, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
- Peter S. Hall & Claire Hulme & Christopher McCabe & Yemi Oluboyede & Jeff Round & David A. Cameron, 2011. "Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence," PharmacoEconomics, Springer Healthcare | Adis, vol. 29(5), pages 415-432.
- Christopher J. McCabe & Tania Stafinski & Richard Edlin & Devidas Menon, 2010. "Access with Evidence Development Schemes: A Framework for Description and Evaluation," PharmacoEconomics, Springer Healthcare | Adis, vol. 28(2), pages 143-152.
When requesting a correction, please mention this item's handle: RePEc:lee:wpaper:1302. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Judy Wright)
If references are entirely missing, you can add them using this form.